Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

G. J. Riely; M. G. Kris; J. L. Marks; A. Li; D. A. Chitale; E. R. Riedel; M. Hsu; W. Pao; V. A. Miller; M. Ladanyi

doi:10.1200/JCO.2008.26.15_SUPPL.8006

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

G. J. Riely
, M. G. Kris
, J. L. Marks
, A. Li
, D. A. Chitale
, E. R. Riedel
, M. Hsu
, W. Pao
, V. A. Miller
, M. Ladanyi

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	26
DOIs	https://doi.org/10.1200/JCO.2008.26.15_SUPPL.8006
State	Published - May 20 2008

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2008.26.15_SUPPL.8006License: Unspecified

Cite this

@article{6a1cb8a956304a98ba7d51646749105b,

title = "Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma",

author = "Riely, \{G. J.\} and Kris, \{M. G.\} and Marks, \{J. L.\} and A. Li and Chitale, \{D. A.\} and Riedel, \{E. R.\} and M. Hsu and W. Pao and Miller, \{V. A.\} and M. Ladanyi",

note = "8006 Background: KRAS mutations are found in ∼ 25\% of lung adenocarcinomas in Western countries and, as a group, are strongly associated with cigarette smoking. These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib.",

year = "2008",

month = may,

day = "20",

doi = "10.1200/JCO.2008.26.15\_SUPPL.8006",

language = "American English",

volume = "26",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

AU - Riely, G. J.

AU - Kris, M. G.

AU - Marks, J. L.

AU - Li, A.

AU - Chitale, D. A.

AU - Riedel, E. R.

AU - Hsu, M.

AU - Pao, W.

AU - Miller, V. A.

AU - Ladanyi, M.

N1 - 8006 Background: KRAS mutations are found in ∼ 25% of lung adenocarcinomas in Western countries and, as a group, are strongly associated with cigarette smoking. These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib.

PY - 2008/5/20

Y1 - 2008/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.8006

U2 - 10.1200/JCO.2008.26.15_SUPPL.8006

DO - 10.1200/JCO.2008.26.15_SUPPL.8006

M3 - Article

VL - 26

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

Disciplines

Access to Document

Other files and links

Cite this